HRP20201435T1 - Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora - Google Patents
Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora Download PDFInfo
- Publication number
- HRP20201435T1 HRP20201435T1 HRP20201435TT HRP20201435T HRP20201435T1 HR P20201435 T1 HRP20201435 T1 HR P20201435T1 HR P20201435T T HRP20201435T T HR P20201435TT HR P20201435 T HRP20201435 T HR P20201435T HR P20201435 T1 HRP20201435 T1 HR P20201435T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitors
- formula
- image
- compound
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 6
- 239000003149 muscarinic antagonist Substances 0.000 title claims 2
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 title 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 title 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000003172 expectorant agent Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 2
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 102000052502 human ELANE Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000000510 mucolytic effect Effects 0.000 claims 2
- 229940066491 mucolytics Drugs 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- -1 pyrazoldiyl Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims 1
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims 1
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Claims (7)
1. Spoj opće formule I
[image]
pri čemu
Q je skupina formule Q1
[image]
Z je H ili OH;
Y je odabran od Y’ i Y1 koje su dvovalentne skupine formule
[image]
ili
[image]
pri čemu
A1 je butilen;
A2 nedostaje ili je (C1-C6)alkilen;
B je odabran iz skupine koju čine pirazoldiil i tiofendiil, opcionalno supstituiran jednom ili više skupina odabranih od metilne;
C je -OC(O)- ili je C1
[image]
pri čemu R4 jest H;
D nedostaje;
n’ je 1;
E je -O-;
G je fenilen;
R1 i R2 neovisno jesu H ili aril;
R3 je skupina formule J1 ili J2
[image]
gdje je R5 skupina formule K
[image]
pri čemu p’ jest 0 ili 1, P nedostaje ili je CO, q nedostaje ili je 1 i W jest heteroaril, te farmaceutski prihvatljive soli ili njihovi solvati.
2. Farmaceutski pripravak koji sadrži spoj formule I kao što je definiran u patentnom zahtjevu 1, s jednim ili više farmaceutski prihvatljivih nosača i/ili ekscipijensa.
3. Spoj formule I prema patentnom zahtjevu I za upotrebu u prevenciji i/ili liječenju bronhoopstruktivnih ili upalnih bolesti.
4. Spoj za upotrebu prema patentnom zahtjevu 3, naznačeno time da bronhoopstruktivne ili upalne bolesti jesu astma ili kronični bronhitis ili kronična opstruktivna plućna bolest (COPD).
5. Kombinacija spoja formule I kao što je definirano u patentnom zahtjevu 1 s jednim ili više aktivnih sastojaka odabranih iz klasa koje čine beta2 agonisti, antimuskarinska sredstva, inhibitori mitogenom aktiviranih proteinskih kinaza (P38 MAP kinaza), inihibitori beta-podjedinice kapa-B kinaze (IKK2) nuklearnog faktora, inhibitori humane neutrofilne elastaze (HNE), inhibitori fosfodiesteraze 4 (PDE4), modulatori leukotriena, nesteroidna protuupalna sredstva (NSAIDs), antitusivna sredstva, regulatori mukusa, mukolitici, ekspektoranski/mukokinetički modulatori, peptidni mukolitici, antibiotici, inhibitori JAK, inhibitori SYK, inhibitori PI3Kdelta ili PI3Kgama, kortikosteroidi i M3-antagonisti/PDE4-inhibitori (MAPI).
6. Farmaceutski pripravak prema patentnom zahtjevu 2 koji se daje inhalacijom, kao što su prašci za inhalaciju, mjerni aerosoli koji sadrže propelant ili formulacije za inhalaciju bez propelanta.
7. Uređaj koji sadrži farmaceutski pripravak prema patentnom zahtjevu 6, koji može biti inhalator jedinične doze ili višestruke doze suhog praška, inhalator s odmjerenom dozom i nebulizer magličastog raspršenja.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195891 | 2012-12-06 | ||
| EP18156043.4A EP3345904B1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201435T1 true HRP20201435T1 (hr) | 2020-11-27 |
Family
ID=47323975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180915TT HRP20180915T1 (hr) | 2012-12-06 | 2018-06-13 | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora |
| HRP20201435TT HRP20201435T1 (hr) | 2012-12-06 | 2020-09-09 | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180915TT HRP20180915T1 (hr) | 2012-12-06 | 2018-06-13 | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8987299B2 (hr) |
| EP (2) | EP2928889B1 (hr) |
| JP (1) | JP6421989B2 (hr) |
| KR (2) | KR102156443B1 (hr) |
| CN (1) | CN104822678B (hr) |
| AR (1) | AR093825A1 (hr) |
| AU (1) | AU2013354043C1 (hr) |
| BR (1) | BR112015012730B1 (hr) |
| CA (1) | CA2893626C (hr) |
| CL (1) | CL2015001483A1 (hr) |
| CO (1) | CO7400870A2 (hr) |
| CY (2) | CY1120159T1 (hr) |
| DK (2) | DK2928889T3 (hr) |
| EA (1) | EA030552B1 (hr) |
| ES (2) | ES2670686T3 (hr) |
| GE (1) | GEP20186839B (hr) |
| HK (1) | HK1212989A1 (hr) |
| HR (2) | HRP20180915T1 (hr) |
| HU (2) | HUE051394T2 (hr) |
| IL (1) | IL239182B (hr) |
| LT (2) | LT3345904T (hr) |
| MA (1) | MA38147B1 (hr) |
| MX (1) | MX369311B (hr) |
| NZ (1) | NZ708738A (hr) |
| PE (1) | PE20151216A1 (hr) |
| PH (1) | PH12015501247A1 (hr) |
| PL (2) | PL2928889T3 (hr) |
| PT (2) | PT2928889T (hr) |
| RS (2) | RS57232B1 (hr) |
| SA (1) | SA515360514B1 (hr) |
| SG (2) | SG10201704032RA (hr) |
| SI (2) | SI2928889T1 (hr) |
| TN (1) | TN2015000244A1 (hr) |
| TR (1) | TR201808698T4 (hr) |
| TW (1) | TWI637954B (hr) |
| UA (1) | UA118181C2 (hr) |
| WO (1) | WO2014086924A1 (hr) |
| ZA (1) | ZA201503965B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| AR093832A1 (es) * | 2012-12-06 | 2015-06-24 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO |
| MA38147B1 (fr) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique |
| MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| TWI731891B (zh) * | 2015-11-16 | 2021-07-01 | 義大利商吉斯藥品公司 | 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法 |
| EP3383867B1 (en) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA2994290C (en) | 2017-11-06 | 2024-01-23 | Entech Solution As | Method and stimulation sleeve for well completion in a subterranean wellbore |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2222128A (en) | 1937-01-29 | 1940-11-19 | Pure Oil Co | Preparation and separation of aromatic hydrocarbons |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| WO2004032921A1 (en) | 2002-10-11 | 2004-04-22 | Pfizer Limited | Indole derivatives as beta-2 agonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CA2543858C (en) | 2003-11-21 | 2014-04-15 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| ATE369333T1 (de) | 2004-01-22 | 2007-08-15 | Pfizer | Sulfonamidderivate zur behandlung von krankheiten |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| WO2005092840A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US7528253B2 (en) | 2004-08-16 | 2009-05-05 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| FR2898640B1 (fr) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| DK3210981T3 (en) | 2009-04-23 | 2019-04-01 | Theravance Respiratory Co Llc | DIAMIDE COMPOUNDS WITH MUSCARINE RECEPTOR ANTAGONIST AND BETA-2 ADDRESSER RECEPTOR AGONIST ACTIVITY |
| WO2010126025A1 (ja) * | 2009-04-30 | 2010-11-04 | 帝人ファーマ株式会社 | 四級アンモニウム塩化合物 |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| PE20141614A1 (es) * | 2011-06-10 | 2014-11-20 | Chiesi Farma Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico |
| KR20180085068A (ko) | 2011-06-10 | 2018-07-25 | 키에시 파르마슈티시 엣스. 피. 에이. | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
| AR093832A1 (es) * | 2012-12-06 | 2015-06-24 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO |
| MA38147B1 (fr) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique |
-
2013
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en active Active
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt active IP Right Grant
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko active IP Right Grant
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja active Active
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active IP Right Grant
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en active Application Filing
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
-
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247A1/en unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
-
2016
- 2016-01-29 HK HK16101057.0A patent/HK1212989A1/zh unknown
-
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
- 2018-06-13 HR HRP20180915TT patent/HRP20180915T1/hr unknown
-
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201435T1 (hr) | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora | |
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| HRP20191257T1 (hr) | Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorbenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol | |
| ES2828070T3 (es) | Métodos para tratar trastornos autoinmunitarios, respiratorios e inflamatorios mediante la inhalación de n-oxido de roflumilast | |
| RU2013142268A (ru) | Фармацевтическая композиция | |
| NZ606548A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| HRP20120832T1 (hr) | Antagonisti muskarinskih acetilkolinskih receptora | |
| WO2009047173A3 (de) | Zerstäuber | |
| DK1719505T3 (da) | Farmaceutiske formuleringer til tørpulverinhalator i form af hårde pellets | |
| CZ302882B6 (cs) | Farmaceutický prostredek | |
| HRP20192010T1 (hr) | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja | |
| HRP20171977T1 (hr) | Derivati dolastatina 10 i auristatina | |
| ZA200600411B (en) | Methods of treating COPD and Pulmonary Hypertension | |
| NO20064161L (no) | Farmasoytiske formuleringer for torrpulverinhalatorer omfattende en aktiv ingrediens med lavdoseringsstyrke | |
| RU2006132040A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| Ambrus et al. | Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties | |
| TW200938232A (en) | Novel dosage and formulation | |
| EA201590030A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент | |
| EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол | |
| ES2797073T3 (es) | Partículas de inhalación que comprenden una combinación de un anticolinérgico, un corticoesteroide y un beta-adrenérgico | |
| US9707228B2 (en) | Dry powder formulation | |
| RU2011140239A (ru) | Фармацевтическая композиция, содержащая стероидное производное (3,2-с)пиразола и второе фармацевтически активное соединение | |
| DK2696871T3 (en) | ACLIDINIUM FOR USE TO IMPROVE SLEEP QUALITY OF RESPIRATORY PATIENTS | |
| RU2012155691A (ru) | Производные сложного аминоэфира алкалоида и их лекарственные композиции | |
| Saha et al. | Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization |